In addition to targeting mutations that drive tumour growth, it is theoretically possible to identify acquired vulnerabilities in cells linked to the loss of tumour suppressors such as SMARCA4, one of the more commonly mutated tumour suppressors in lung cancers. This evidence concerns the gene SMARCA4 and neoplasm.